Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of APL-130277 (Kynmobi) for OFF Episodes in Parkinson's Disease
NCT02228590Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by Sumitomo Pharma America. Primary endpoints: Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State, Time to 'ON' State From Time of Dosing and 7 more. Started Aug 2014; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02228590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228590.